Startup Dossier
BiPER Therapeutics
Strasbourg-based biotech developing first-in-class oral small molecules that selectively inhibit BiP (GRP78) to overstress and destroy pathological cells, with an initial focus on gastrointestinal cancers.
active
Typestartup
SectorBioTech
LocationStrasbourg
About
Strasbourg-based biotech developing first-in-class oral small molecules that selectively inhibit BiP (GRP78) to overstress and destroy pathological cells, with an initial focus on gastrointestinal cancers.
Structural DNA
Legal Name
BiPER Therapeutics
SIREN
902070838
Founders & Team
Funding Lineage
Seed
France 2030 (Lead)
€1.0M
Dec 2025
Seed
WiSEED (Lead)
€300K
Feb 2023
Programs
i-Lab
2022Pharmacie & biotechnologies